SCHEMBL4964464

SCHEMBL4964464

O=S(=O)(Cl)CCc1cc(F)ccc1Br

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APLNR P35414 2/20 0.42
PSEN1 P49768 1/20 0.37
PSEN2 P49810 1/20 0.37
APH1B Q8WW43 1/20 0.37
NCSTN Q92542 1/20 0.37
APH1A Q96BI3 1/20 0.37
PSENEN Q9NZ42 1/20 0.37
KMT2A Q03164 1/20 0.34
PTGES2 Q9H7Z7 3/20 0.33
FFAR1 O14842 1/20 0.32
FFAR4 Q5NUL3 1/20 0.32
PKM P14618 1/20 0.32
HTR2A P28223 1/20 0.31
HTR2C P28335 1/20 0.31
RIPK1 Q13546 1/20 0.31
CA2 P00918 1/20 0.31
DPP4 P27487 1/20 0.30
ALDH1A1 P00352 1/20 0.30
POLB P06746 1/20 0.30
GRK2 P25098 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20188380 0.86 APLNR (0.42) APLNRPSEN1PSEN2APH1BNCSTN
SCHEMBL4967995 0.81 PSEN1 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4968002 0.81 PSEN1 (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL4967989 0.81 PKM (0.34) APLNRPSEN1PSEN2APH1BNCSTN
SCHEMBL4967201 0.81 TSHR (0.37) APLNRKMT2APTGES2CA2
SCHEMBL4965370 0.76 DPP4 (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL17979919 0.76 PKM (0.36) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL5162483 0.74 FFAR1 (0.44) APLNRPSEN1PSEN2APH1BNCSTN
SCHEMBL848881 0.74 TAAR1 (0.50) APLNRPTGES2CA2L3MBTL1
SCHEMBL31627087 0.74 TAAR1 (0.50) APLNRPTGES2CA2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-07-17 US disclosed
WO-2008073956-A2 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE WYETH (US) 2008-06-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080171737-A1 CYCLIC SULFONAMIDE DERIVATIVES AND METHODS OF THEIR USE SLC6A4, SLC6A2, SLC6A3 APLNR 3069/4885PSEN1 794/4885PSEN2 634/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.